Home > Oncology > ASCO 2022 > Ifosfamide is likely to be the go-to therapy in recurrent Ewing sarcoma

Ifosfamide is likely to be the go-to therapy in recurrent Ewing sarcoma

Presented By
Dr Martin McCabe, University of Manchester, UK
Conference
ASCO 2022
Trial
Phase 3, rEECur
Ifosfamide was more efficacious than topotecan plus cyclophosphamide in patients with primary recurrent or refractory Ewing sarcoma, despite a higher discontinuation rate due to toxicity in the ifosfamide arm. The phase 3 rEECur trial is the first randomised study to deliver efficacy, safety, and quality-of-life data to inform physicians on chemotherapy treatment decisions for patients with recurrent Ewing sarcoma. Dr Martin McCabe (University of Manchester, UK) noted that there is no established standard-of-care for patients with recurrent/refractory Ewing sarcoma, because there have not been any randomised trials comparing different chemotherapy regimens in this population [1]. Therefore, the phase 3 rEECur trial randomised patients with previously treated Ewing sarcoma to ifosfamide (IFOS; n=78) or topotecan and cyclophosphamide (TC; n=162). The primary outcome was event-free survival (EFS). The median EFS was numerically higher in the IF...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on